Moving Medicine
What to know about FDA-approved cannabis-derived products
Dec 5, 2024
Randy Easterling, a seasoned family practitioner and past president of the Mississippi Medical Association, dives into the world of FDA-approved cannabis-derived medications. He discusses their specific uses, such as Epidiolex, and navigates the complex regulatory landscape surrounding them. Listeners learn about the challenges in cannabis research, the legal status of THC and CBD in foods, and the importance of evidence-based studies, especially for vulnerable populations. This enlightening conversation sheds light on a rapidly evolving field.
09:34
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The FDA has approved four cannabis-derived products, primarily for specific medical uses, following rigorous safety and efficacy trials.
- Regulatory challenges and the Schedule I classification of cannabis significantly limit research opportunities and hinder the development of new cannabis medications.
Deep dives
Understanding FDA-Approved Cannabis Products
The FDA has not approved cannabis for treating any specific disease or condition; however, there are four FDA-approved products derived from cannabis or its compounds. These include Epidiolex, which is highly purified CBD used to treat pediatric epilepsy and certain seizure disorders, as well as Marinol and Syndros, variations of the cannabinoid Dronabinol used for appetite loss in AIDS patients and nausea from chemotherapy. Additionally, Nabilone (Sesamet) is approved for chemotherapy-induced nausea and vomiting. The rigorous FDA approval process requires randomized, double-blind trials to prove both safety and efficacy before any cannabis-related product can be legally marketed.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
